Introduction
The international outbreak of respiratory illness termed coronavirus disease 2019 (COVID-19) began in December 2019 and has affected millions of individuals worlwide. There are various therapeutic agents approved by FDA for COVID-19. For instance, favipiravir is reported as one of the possible medications for shortening the duration of COVID-19 symptoms, by reducing inflammation. Here, we report the case of a 57-year-old man presented with fever and dry cough, who had COVID-19 infection and later presented with erosions in oral, anogenital regions and dorsum of his hands.